"The venom of the Gila monster, through its peptide exendin-4, has paved the way for new diabetes and obesity treatments such as Ozempic and Wegovy."
"Daniel J. Druckerâs pioneering research in the late 1990s identified the potential of GLP-1 receptor agonists, transforming diabetes treatment by utilizing the properties of Gila monster venom."
The venom of the Gila monster has been instrumental in developing treatments for diabetes and obesity via GLP-1 receptor agonists like Ozempic and Wegovy. Specific components of the venom, particularly the peptide exendin-4, stimulate insulin release and regulate appetite by mimicking the naturally occurring GLP-1 hormone. This discovery stemmed from pioneering work by endocrinologist Daniel J. Drucker and Dr. John Eng, who explored how Gila monstersâ unique metabolic processes could be harnessed to create long-lasting therapeutic agents for managing blood sugar levels and reducing body weight.
Read at New York Post
Unable to calculate read time
Collection
[
|
...
]